Organogenesis Holdings Inc. ORGO
Organogenesis is a leading regenerative medicine company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care and surgical and sports medicine markets.
Our mission is advancing healing and recovery beyond expectations. Several of our existing and pipeline products in our portfolio have Premarket Application ("PMA") approval, or 510(k) clearance from the United States Food and Drug Administration ("FDA"). Our solutions address large and growing markets driven by aging demographics and increases in comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease. We offer our differentiated products and in-house customer support to a wide range of health care customers including hospitals, wound care centers, government facilities, ambulatory surgery centers ("ASCs") and physician offices.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $564.2M | $482.0M | $433.1M | $450.9M | $467.4M | $338.3M | $261.0M | $193.4M | $198.5M | $138.7M |
| Cost of revenue | — | $115.7M | $106.5M | $105.0M | $114.2M | $87.3M | $75.9M | $68.8M | $61.2M | $48.2M |
| Gross profit | — | $366.3M | $326.7M | $345.9M | $353.2M | $251.0M | $185.0M | $124.6M | $137.3M | $90.5M |
| R&D | $44.5M | $50.3M | $44.4M | $39.8M | $30.7M | $20.1M | $14.8M | $10.7M | $9.1M | $6.3M |
| SG&A | $326.2M | $294.5M | $269.8M | $283.8M | $250.2M | $204.2M | $200.1M | $162.0M | $133.7M | $93.0M |
| Total operating expenses | $519.5M | $483.3M | $420.6M | $323.6M | $280.9M | $224.3M | $214.9M | $176.2M | $142.8M | $99.3M |
| Operating income | $44.7M | -$1.3M | $12.5M | $22.3M | $72.2M | $26.7M | -$29.9M | -$51.6M | -$5.5M | -$8.8M |
| Interest expense | $2.3M | $1.5M | $2.2M | $2.0M | $7.2M | $11.3M | $9.0M | $10.8M | $8.0M | $5.6M |
| Pre-tax income | $47.0M | -$2.8M | $10.4M | $20.3M | $63.1M | $17.8M | -$38.6M | -$64.7M | -$14.6M | -$14.7M |
| Income tax | $9.9M | $3.7M | $5.4M | $4.8M | $31.1M | $530.0K | $150.0K | $84.0K | $7.0M | $65.0K |
| Net income | $37.0M | $900.0K | $4.9M | $15.5M | $94.2M | $17.2M | -$38.7M | -$64.8M | -$8.4M | -$17.0M |
| EPS, basic | 0.16 | -0.01 | 0.04 | 0.12 | 0.73 | 0.16 | -0.42 | -0.94 | — | — |
| EPS, diluted | 0.15 | -0.01 | 0.04 | 0.12 | 0.70 | 0.15 | -0.42 | -0.94 | -0.14 | -0.27 |
| Shares, diluted (wtd. avg.) | 130.2M | 131.7M | 132.7M | 132.4M | 133.7M | 111.4M | 92.8M | 69.3M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $93.7M | $135.6M | $104.3M | $103.3M | $114.5M | $84.8M | $60.4M | $21.4M | $2.4M | $1.9M |
| Receivables | $217.5M | $109.9M | $82.0M | $89.5M | $82.5M | $56.8M | $39.4M | $34.1M | $28.1M | — |
| Inventory | $29.6M | $26.2M | $28.3M | $24.8M | $25.0M | $27.8M | $22.9M | $13.3M | $14.3M | — |
| Total current assets | $362.2M | $285.9M | $225.0M | $222.6M | $227.0M | $174.3M | $125.6M | $71.1M | $49.7M | $1.4M |
| Property, plant and equipment | $103.7M | $89.1M | $116.2M | $102.5M | $79.2M | $55.8M | $47.2M | $39.6M | $42.1M | — |
| Goodwill | $28.8M | $28.8M | $28.8M | $28.8M | $28.8M | $28.8M | $25.5M | $25.5M | $25.5M | — |
| Other intangibles | $9.1M | $12.5M | $15.9M | $20.8M | $25.7M | $30.6M | $20.8M | $26.1M | $29.8M | — |
| Total assets | $598.7M | $497.9M | $460.0M | $449.4M | $443.3M | $290.2M | $220.7M | $163.7M | $148.7M | $311.4M |
| Accounts payable | $31.9M | $28.9M | $30.7M | $32.3M | $29.3M | $23.4M | $28.4M | $19.2M | $19.1M | — |
| Total current liabilities | $100.1M | $77.5M | $80.5M | $75.0M | $82.7M | $68.2M | $59.9M | $56.1M | $52.0M | $478.4K |
| Long-term debt | — | — | $66.6M | $71.2M | $74.1M | $70.0M | $49.6M | — | $52.1M | — |
| Total liabilities | $164.8M | $112.6M | $181.4M | $183.7M | $201.9M | $148.4M | $165.1M | $116.6M | $157.3M | $11.3M |
| Retained earnings | -$3.1M | -$40.1M | -$41.0M | -$45.3M | -$60.8M | -$155.0M | -$171.0M | -$130.2M | -$65.4M | -$233.9K |
| Total equity | $300.1M | $262.9M | $278.7M | $265.7M | $241.3M | $141.8M | $52.0M | $39.9M | -$15.3M | -$16.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.3M | $14.2M | $30.9M | $24.9M | $62.0M | $5.5M | -$33.5M | -$60.6M | -$3.5M | -$4.9M |
| Depreciation and amortisation | $15.3M | $13.6M | $10.4M | $5.8M | $5.8M | $4.4M | $3.8M | $3.3M | $3.6M | $5.7M |
| Stock-based compensation | $13.3M | $10.6M | $9.0M | $6.6M | $3.9M | $1.7M | $936.0K | $1.1M | $919.0K | $473.0K |
| Capital expenditure | $14.2M | $10.0M | $24.4M | $33.9M | $31.2M | $17.7M | $6.0M | $1.9M | $2.4M | $1.4M |
| Investing cash flow | -$14.2M | -$10.0M | -$24.4M | -$33.9M | -$31.2M | -$23.5M | -$6.2M | -$1.9M | -$14.9M | -$1.2M |
| Financing cash flow | -$17.4M | $27.6M | -$5.5M | -$2.2M | -$1.0M | $42.5M | $78.7M | $81.5M | $18.9M | $6.8M |
| Buybacks | — | $25.5M | $0 | $0 | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-197357.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $138.7M | $198.5M | $193.4M | $261.0M | $338.3M | $467.4M | $450.9M | $433.1M | $482.0M | $564.2M |
| Gross profit | $90.5M | $137.3M | $124.6M | $185.0M | $251.0M | $353.2M | $345.9M | $326.7M | $366.3M | — |
| Net income | -$17.0M | -$8.4M | -$64.8M | -$38.7M | $17.2M | $94.2M | $15.5M | $4.9M | $900.0K | $37.0M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Item 5.02
- Material agreement signed Item 1.01
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |